DNDN's been pretty flat past week, so I'm not that concerned. Seems to be missing the whole biotech bubble that's going on.
Provenge is still a POS drug, and it will take more than a new CEO to polish that turd.
"You can't teach stupid it just comes natural eh?"
I think there's a course in that, but it was one of those advanced courses in grad school: for PhD students only.
"I think we'll get a continue and you'll be able to get out at around 5."
I'd be OK with 5, but I think it will be closer to 4 after the secondary.
"Wow, there are so many stocks with a better risk reward than shorting this one"